CAR-M-c-MET(Peking Union Medical College, Chinese Academy of Medica…

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 15 October 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 1

Clinical phase

Not yet recruiting

Recruitment status

not reported

Planned enrollment

2028-12-01

Primary-completion proxy

Executive view

NCT07553793 evaluates CAR-M-c-MET(Peking Union Medical College, Chinese Academy of Medical Sciences) in Advanced Pancreatic Adenocarcinoma. The disclosed sponsor is Peking Union Medical College Hospital, the design is Interventional, and the geographic footprint is China. The first listed primary endpoint is Dose-Limiting Toxicity (DLT), assessed over from the start point of cell infusion to 28 days after cell infusion for each patient.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07553793 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Advanced Pancreatic Adenocarcinoma landscape. Drug & Asset MCP drug_fetch was queried for CAR-M-c-MET(Peking Union Medical College, Chinese Academy of Medical Sciences), while Company & Deal Intelligence MCP organization_fetch was queried for Peking Union Medical College Hospital.

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT07553793	CAR-M-c-MET(Peking Union Medical College, Chinese Academy of Medical Sciences)	Phase 1 / Not yet recruiting	Peking Union Medical College Hospital	China	Dose-Limiting Toxicity (DLT) from the start point of cell infusion to 28 days after cell infusion…	2028-12-01
NCT07594626	Pemetrexed Dipotassium	Phase 1/2 / Recruiting	Northwestern University	United States	Dose limiting toxicity Up to 21 days	2030-12-09
NCT07595172	Adebrelimab	Phase 1/2 / Recruiting	West China Hospital	China	Objective response rate (RECIST v1.1) From the first patient enrollment until 6 months after the last patie…	2028-08-01
NCT07597772	68Ga-SNA014	Early Phase 1 / Recruiting	Suzhou SmartNuclide Biopharmaceutical Co., Ltd.	China	The safety and tolerability profile of [68Ga]Ga-NODAGA-SNA014 in patients with CLDN18.2-positive pancreatic cancer. 1 week	2026-07-01
NCT07594067	Fludarabine Phosphate	Phase 1 / Recruiting	University of Pennsylvania	United States	Number of Subjects with treatment related adverse events using NCI Common Terminology Criteria for Adverse Events (CTCA… Up to 15 years following TCR1188-ABC cell administration	2042-11-01

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT07553793 is a Phase 1, not yet recruiting study with not reported planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.

The primary endpoint is “Dose-Limiting Toxicity (DLT)” over “from the start point of cell infusion to 28 days after cell infusion for each patient.” The retrieved endpoint description is: Any clinically significant Grade 3 or higher toxicity involving a major organ system, as defined by NCI CTCAE version 5, occurring within 28 days post-infusion and persisting for more than 72 hours; II. Any Grade 4 Cytokine Release Syndrome (CRS) occurring during the treatment period that does not resolve to Grade 2 or lower within 72 hours, or any death attributed to CRS; III. Any Grade 3 CRS occurring during the treatment period that does not resolve to Grade 2 or lower within 7 days; IV. Any Grade 3 or higher autoimmune toxicity occurring during the.

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of not reported should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

0 recent result records were selected as contextual evidence for Advanced Pancreatic Adenocarcinoma. These records do not establish direct evidence for NCT07553793 unless the registration number matches.

Indexed evidence status

No directly comparable result record was retrieved for this disease query. This is a monitoring gap, not evidence of absence.

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

CAR-M-c-MET(Peking Union Medical College, Chinese Academy of Medical Sciences) is indexed as CAR-M with target not reported biology and a global stage of Phase 1. The asset profile lists Beijing Union Medical College Hospital, Chinese Academy of Medical Sciences as an originator or developer.

Peking Union Medical College Hospital is indexed in an unreported country with the website http://www.pumch.cn/index.html. Peking Union Medical College Hospital is a healthcare center that focuses on clinical care, medical research, and educational services. The record lists 43 development-stage drug assets.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether CAR-M-c-MET(Peking Union Medical College, Chinese Academy of Medical Sciences) is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT07553793
Protocol source: https://clinicaltrials.gov/study/NCT07553793
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 15 October 2026.

CAR-M-c-MET(Peking Union Medical College, Chinese Academy of Medical Sciences) in Advanced Pancreatic Adenocarcinoma is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Dose-Limiting Toxicity (DLT) and 2028-12-01 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP